Hormonal consequences and prognosis of chronic heart failure

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 3, 2011, Pages 224-230

  Attanasio, Philipp ^a   Anker, Stefan D ^a,b   Doehner, Wolfram ^a,c   Von Haehling, Stephan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c Center for Cardiovascular Research (CCR)   (Germany)

Author keywords

Adipokines; anabolic catabolic disbalance; appetite regulation; cardiac cachexia; chronic heart failure

Indexed keywords

ADIPONECTIN; ANDROGEN; GHRELIN; GROWTH HORMONE; LEPTIN;

ARTICLE; CACHEXIA; DISEASE COURSE; ENDOCRINE DISEASE; FOOD INTAKE; HEART FAILURE; HUMAN; PROGNOSIS;

ADIPONECTIN; APPETITE; CACHEXIA; CHRONIC DISEASE; GHRELIN; HEART FAILURE; HUMAN GROWTH HORMONE; HUMANS; LEPTIN; PEPTIDE HORMONES; PROGNOSIS; SIGNAL TRANSDUCTION; TESTOSTERONE;

EID: 79955576882     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283469505     Document Type: Article

References (86)

1. American Heart Association. Heart disease and stroke statistics 2005 update. Dallas, Texas: American Heart Association; 2005.
2. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-2018.
3. McMurray JJ, Stewart S. Epidemiology, aetiology and prognosis of heart failure. Heart 2000; 83:596-602. (Pubitemid 30316742)
4. Stewart S, MacIntyre K, Hole DJ, et al. More 'malignant' than cancer? Fiveyear survival following a first admission for heart failure. Eur J Heart Fail 2001; 3:315-322. (Pubitemid 32895839)
5. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: Facts and numbers. J Cachexia Sarcopenia Muscle 2010; 1:1-5.
6. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349:1050-1053. (Pubitemid 27158249)
7. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: Facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010; 1:129-133. An overview of sarcopenia, its prevalence, phenotype, and clinical importance in ageing and chronic diseases.
8. Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992; 85:1364-1373.
9. Schulze PC, Linke A, Schoene N, et al. Functional and morphological skeletal muscle abnormalities correlate with reduced electromyographic activity in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2004; 11:155-161. (Pubitemid 38591087)
10. Jankowska EA, Jakubaszko J, Cwynar A, et al. Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. Eur J Heart Fail 2009; 11:28-38. This study showed significant bone loss over time in 35% of male patients with CHF.
11. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42:1933-1940. (Pubitemid 37485568)
12. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8:216-224.
13. Holm C. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem Soc Trans 2003; 31:1120-1124. (Pubitemid 38030921)
14. von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007; 50:1973-1980. (Pubitemid 350046336)
15. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20:683-693. (Pubitemid 29204354)
16. Springer J, von Haehling S, Anker SD. The need for a standardized definition for cachexia in chronic illness. Nat Clin Pract Endocrinol Metab 2006; 2:416-417. (Pubitemid 44214045)
17. Evans WJ, Morley JE, Argilés J, et al. Cachexia: A new definition. Clin Nutr 2008; 27:793-799.
18. von Haehling S, Anker SD. Future prospects of anticytokine therapy in chronic heart failure. Expert Opin Investig Drugs 2005; 14:163-176. (Pubitemid 40403390)
19. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: An overview. Heart 2004; 90:464-470. (Pubitemid 38406929)
20. Ho KK, O'Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. Endocr J 1996; 43 (Suppl):S57-S63. (Pubitemid 27014289)
21. Andreassen M. The growth hormone/insulin-like growth factor-I system in chronic heart failure and its interaction with adiponectin. Eur J Heart Fail 2010; 12:1154-1155.
22. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13:113-170. (Pubitemid 36986557)
23. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone. J Am Coll Cardiol 2001; 38:443-452. (Pubitemid 32725023)
24. Dalla Libera L, Ravara B, Volterrani M, et al. Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure. Am J Physiol Cell Physiol 2004; 286:C138-C144. (Pubitemid 38055822)
25. Watanabe S, Tamura T, Ono K, et al. Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: Association with adiponectin. Eur J Heart Fail 2010; 12:1214-1222.
26. Lund LH, Freda P, Williams JJ, et al. Growth hormone resistance in severe heart failure resolves after cardiac transplantation. Eur J Heart Fail 2009; 11:525-528.
27. Genth-Zotz S, Zotz R, Geil S, et al. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: Effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 1999; 99:18-21. (Pubitemid 29035951)
28. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334:809-814. (Pubitemid 26099602)
29. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebocontrolled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351:1233-1237. (Pubitemid 28181962)
30. Isgaard CH, Bergh K, Caidahl K, et al. A placebo controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998; 19:1704-1711. (Pubitemid 28524190)
31. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785-792. (Pubitemid 29420473)
32. Bagatell CJ, Bremner WJ. Androgens in men: Uses and abuses. N Engl J Med 1996; 334:707-714.
33. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results form the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87:589-598. (Pubitemid 34158223)
34. O'Donnell AB, Travison TG, Harris SS, et al. Testosterone, dehydroepiandrosterone, and physical performance in older men: Results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2006; 91:425-431. (Pubitemid 43236905)
35. Jankowska EA, Drohomirecka A, Ponikowska B, et al. Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. Eur J Heart Fail 2010; 12:966-973.
36. Shores MM, Moceri VM, Sloan KL, et al. Low testosterone levels predict incident depressive illness in older men: Effects of age and medical morbidity. J Clin Psychiatry 2005; 66:7-14.
37. Debigaré R, Marquis K, Côté CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003; 124:83-89. (Pubitemid 36851335)
38. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am 2007; 36:333-348. (Pubitemid 46817893)
39. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: Prevalence and detrimental impact on survival. Circulation 2006; 114:1829-1837. (Pubitemid 44673358)
40. Jankowska EA, Filippatos G, Ponikowska B, et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail 2009; 15:442-450.
41. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54:919-927.
42. Handelsman DJ. Inadequate masking of testosterone. J Am Coll Cardiol 2010; 55:2290; author reply 2290-2291.
43. Jankowska EA, Rozentryt P, Ponikowska B, et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA 2009; 301:1892-1901.
44. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000; 283:763-770. (Pubitemid 30084616)
45. Yeh SS, DeGuzman B, Kramer T, M012 Study Group. Reversal of COPDassociated weight loss using the anabolic agent oxandrolone. Chest 2002; 122:421-428. (Pubitemid 35002116)
46. Gü der G, Frantz S, Bauersachs J, et al. Low circulating androgens and mortality risk in heart failure. Heart 2010; 96:504-509.
47. Wehr E, Pilz S, Boehm BO, et al. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail 2011. [Epub ahead of print]
48. Brunetti L, Di Nisio C, Orlando G, et al. The regulation of feeding: A cross talk between peripheral and central signalling. Int J Immunopathol Pharmacol 2005; 18:201-212. (Pubitemid 40825883)
49. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141:4255-4261.
50. Date Y, Nakazato M, Hashiguchi S, et al. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002; 51:124-129. (Pubitemid 34517988)
51. Mori K, Yoshimoto A, Takaya K, et al. Kidney produces a novel acylated peptide, ghrelin. FEBS Lett 2000; 486:213-216.
52. Gualillo O, Caminos J, Blanco M, et al. Ghrelin, a novel placental-derived hormone. Endocrinology 2001; 142:788-794. (Pubitemid 32222428)
53. Iglesias MJ, Pineiro R, Blanco M, et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res 2004; 62:481-488. (Pubitemid 38648962)
54. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660. (Pubitemid 129516334)
55. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50:2540-2547. (Pubitemid 33642772)
56. Sakata I, Yamazaki M, Inoue K, et al. Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion. Neurosci Lett 2003; 342:183-186. (Pubitemid 36570348)
57. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: Relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104:2034-2038. (Pubitemid 33027043)
58. Lund LH, Williams JJ, Freda P, et al. Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation. Eur J Heart Fail 2009; 11:789-794. The findings of this study suggest the state of ghrelin resistance in CHF.
59. Scacchi M, Ida Pincelli A, Cavagnini F. Nutritional status in the neuroendocrine control of growth hormone secretion: The model of anorexia nervosa. Front Neuroendocrinol 2003; 24:200-224. (Pubitemid 37329472)
60. Beiras-Fernandez A, Kreth S, Weis F, et al. Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure. Peptides 2010; 31:2222-2228.
61. Akamizu T, Kangawa K. Ghrelin for cachexia. J Cachexia Sarcopenia Muscle 2010; 1:169-176.
62. Mü ller TD, Perez-Tilve D, Tong J, et al. Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia. J Cachexia Sarcopenia Muscle 2010; 1:159-167.
63. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110:3674-3679. (Pubitemid 39665256)
64. Gaucher EA, Miyamoto MM, Benner SA. Evolutionary, structural and biochemical evidence for a new interaction site of the leptin obesity protein. Genetics 2003; 163:1549-1553. (Pubitemid 36523404)
65. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: A review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26:1407-1433. (Pubitemid 36007818)
66. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411:480-484. (Pubitemid 32494394)
67. Anker SD, Egerer KR, Volk HD, et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79:1426-1430.
68. Schulze PC, Kratzsch J, Linke A, et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003; 5:33-40. (Pubitemid 36205542)
69. Doehner W, Pflaum CD, Rauchhaus M, et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol 2001; 145:727-735. (Pubitemid 33133679)
70. Paolisso G, Tagliamonte MR, Galderisi M, et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 1999; 34:1047-1052.
71. Nickola MW, Wold LE, Colligan PB, et al. Leptin attenuates cardiac contraction in rat ventricular myocytes: Role of NO. Hypertension 2000; 36:501-505.
72. McGaffin KR, Moravec CS, McTiernan CF. Leptin signaling in the failing and mechanically unloaded human heart. Circ Heart Fail 2009; 2:676-683.
73. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009; 73:608-614.
74. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279:12152-12162. (Pubitemid 38445780)
75. Tsuchida A, Yamauchi T, Ito Y, et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004; 279:30817-30822. (Pubitemid 38938015)
76. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361:226-228. (Pubitemid 36126226)
77. Otsuka F, Sugiyama S, Kojima S, et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in nondiabetic men. Circ J 2007; 71:1703-1709. (Pubitemid 350240089)
78. Haugen E, Furukawa Y, Isic A, et al. Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: A hospital cohort study. Int J Cardiol 2008; 125:216-219.
79. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112:1756-1762. (Pubitemid 41372115)
80. McEntegart MB, Awede B, Petrie MC, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: Relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007; 28:829-835. (Pubitemid 47343601)
81. Araú jo JP, Lourenço P, Rocha-Gonçalves F, et al. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail 2009; 11:567-572.
82. Shinmura K. Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail Rev 2010; 15:457-466.
83. Van Berendoncks AM, Garnier A, Beckers P, et al. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 2010; 3:185-194.
84. Laoutaris ID, Vasiliadis IK, Dritsas A, et al. High plasma adiponectin is related to low functional capacity in patients with chronic heart failure. Int J Cardiol 2010; 144:319-320.
85. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009; 53:2070-2077.
86. von Haehling S, Lainscak M, Doehner W, et al. Diabetes mellitus, cachexia and obesity in heart failure: Rationale and design of the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle 2010; 1:187-194. SICA-HF is the first multinational large-scale study of cachectic heart failure prevalence, incidence, and phenotype. The article describes the rationale and design of the study.